Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study

Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3...

Descripción completa

Detalles Bibliográficos
Autores: Quiroga, Borja, Soler, María José, Ortiz Arduán, Alberto, Jaravaca Mantecón, Carlos Jesús, Nava Pérez, Nathasha, Serra Martín, Marta, Sato, Yurika, Marin Franco, Antonio José, Pazmiño Zambrano, Diana Flor, Lucena Valverde, Rafael, Ortega Diaz, Mayra, Calderón González, Carmen, Cazorla López, Juan Manuel, Pereira, Mónica, González Parra, Emilio José, Sánchez Horrillo, Ana, Sánchez González, María Carmen, Toapanta, Néstor, Cigarrán Guldris, Secundino, Sánchez Hernández, Rosa, Pizarro Sánchez, Soledad, Muñiz Rincón, María, Garcia-Fernández, Nuria, Blanco Castro, Natalia, Collantes Mateo, Rocío, Quiroz Morales, Manuel Augusto, Escamilla-Cabrera, Beatriz, Berdud Godoy, Isabel, Gil-Casares Casanova, Beatriz, Leyva, Alba, Rojas, José, Gansevoort, Ron T., De Sequera, Patricia, Carretero, Marta Puerta, Tocora, Daniel Gaitán, Rodríguez, Mª Teresa Jaldo, Zanón, Tamar Talaván, Rodriguez Suárez, Esther, Sáenz Santolaya, Alfredo José, Calero, Raquel Cerrajero, Cobo, Patricia Arribas, Ramos, Patricia Muñoz, Gracia Iguacel, Carolina Marta, Martín Cleary, Catalina, Sánchez-Rodríguez, Jinny, Ramos-Verde, Ana, Giraldo, Yohana Gil, Suárez, Pablo Ruano, Perpén, Antonio Fernández, Ramos, Andrés Fernández, Villanueva, Laura Salanova, Cortiñas, Alejandra, Díez Arias, Pablo A., Cárdenas, Alicia Cabrera, De Santos, Antonio, Núñez, Almudena, Cuadrado, Guillermina Barril, Repollet, Raquel, Moreso, Francesc, Azancot, María Antonieta, Ramos, Natalia, Bestard, Oriol, Cidraque, Ignacio, Bermejo, Sheila, Agraz, Irene, Prat, Oreto, Medina, Carlota, Pardo, Emma, Saiz, Alejandro, Granados, Nicolás Menéndez, Cabo, María Jesús Corton, Alarcón, W. L., Alexandru, Simona, Suarez, Laura García Puente, Saico, Saul Pampa, Tapia, Marisol Poma, Osorio, Laura Rodríguez, Zamora, Rocío, Moreno, Paloma Leticia Martin, González, Noelia Ania, Ortiz, Ana Sabalza, Iñarrea, María Nieves Bastida, García, Teresa, Narváez, Carlos, Orellana, Cristhian, León, José Luis Pizarro, Martínez García, Manuel Antonio, Jiménez, Benaldina García, Moya, Juan De Dios Ramiro, Espinosa, D. L., Herrador, Alejandro Jiménez, Zurita, Manuel Navarro, Álvarez, Leonardo Díaz, Martínez, Álvaro González, Arroyo, Sandra Báez, Fernández, Raquel Reina, Vargas, Marlyn Janella Suárez, Casero, Rocío Calurano, Useche, Gustavo, De Miguel, Carmen Santamaría
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/714577
Acceso en línea:http://hdl.handle.net/10486/714577
https://dx.doi.org/10.1093/ckj/sfac169
Access Level:acceso abierto
Palabra clave:booster
COVID-19
hemodialysis
SARS-CoV-2
vaccination
Medicina
Descripción
Sumario:Background: Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods: This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results: A total of 711 patients [67% male, median age (range) 67 (20-89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P =. 001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P =. 693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P =. 001), lower time from booster (P =. 043) and past breakthrough SARS-CoV-2 infection (P <. 001). Conclusions: In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection

Similares en LA Referencia